BirchBioMed is a clinical-stage biomedical company
focused on the clinical evaluation, development and commercialization of anti-scarring drugs,
autoimmune therapeutics and novel strategies for transplantation.
POSITIVE TOPLINE DATA FROM PHASE 2 STUDY OF FS2
FOR TREATMENT OF KELOID SCARS
Birchbiomed Is Cleared To Begin First-of-its-kind Phase II Clinical Trial For Ground-Breaking Anti-Scarring Drug
Sensus Healthcare Launches Collaboration with BirchBioMed to Treat and Prevent Scarring for Keloids Patients Around the World
BirchBioMed’s Scientific Advisory Board Member Dr. Aziz Ghahary is the 2017 British Columbia Professional Fire Fighters Burn Fund Honouree